BMS 303141 Property

Boiling point:

591.5±60.0 °C(Predicted)

Density 

1.462±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: soluble20mg/mL, clear

form 

powder

pka

4.94±0.48(Predicted)

color 

white to beige

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

Safety

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

BMS 303141 Chemical Properties,Usage,Production

Description

BMS-303141 (943963-47-8) is a potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 μM. Inhibits lipid biosynthesis, IC50=8 μM in HepG2 cells.1,2?Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2?A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2?Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3?Reduces cell cycle progression in iBN cells.4

Uses

BMS-303141 has been used for inhibition of ATP citrate lyase in breast cancer cell lines.

Definition

ChEBI: 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide is a member of biphenyls.

Biochem/physiol Actions

BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model.

storage

Store at -20°C

References

1) Li?et al. (2007),?2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors; Bioorg. Med. Chem.,?17?3208 2) Ma?et al.?(2009),?A novel direct homogeneous assay for ATP citrate lyase; J. Lipid Res.,?50?2131 3) Shah?et al.?(2016),?Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism; Oncotarget,?7?43713 4) Rhee and Dekoter (2017),?Regulation of Lipid Metabolism and Cell Cycle Progression by PU.1 in Myeloid Progenitor Cells; Blood,?130?2433